Mike Lazur, Noesis vets form new agency, Lazur Hoyvald Goldstein Partners

Share this article:

Former Torre Lazur McCann Healthcare chief creative director Mike Lazur, and Commonhealth’s Noesis veterans Christian Hoyvald and Steven Goldstein joined forces to become managing partners of a new agency, Lazur Hoyvald Goldstein Partners.

The agency opened the doors to its offices this April in Bridgewater, NJ.

All three partners see brand-building as their principle goal and believe they have a “nice mixture” of backgrounds, the trio told MM&M during a recent phone interview.

Lazur started out as an art director and has been a creative director for most of his more than 30 years in the industry. Hoyvald spent 14 years on the client side, holding positions in senior brand management, finance and market research at Novartis, Bristol-Myers Squibb and Reliant Pharmaceuticals. Four years ago, he joined Noesis ultimately serving as its EVP, director of client services. Goldstein was SVP, creative director at Noesis and a member of the CommonHealth Management committee. He has worked on several award-winning campaigns throughout his 20-year career.

Of the four clients currently signed on with Lazur Hoyvald Goldstein, one is a large chain of diagnostic radiology centers, one is a manufacturer of globally marketed oral specimen collection and diagnostic devices, and another is a long-established manufacturer of prescription dermatological and surgical products.

Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...